Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-04
2006-07-04
Murphy, Joseph (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000, C435S375000, C435S007210
Reexamination Certificate
active
07071159
ABSTRACT:
The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.
REFERENCES:
patent: WO 92/14748 (1992-09-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11499 (1994-05-01), None
Conn, G. et al. “Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor”, Proc., Natl. Acad. Sci. USA, 1990, vol. 87, pp. 2628-2632.
Ferrara, N. & Henzel W. “Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells”, Biochem. and Biophys. Res. Comm., 1989, vol. 161, pp. 851-858.
Gospodarowicz, D. et al. “Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells”, Proc. Natl. Acad. Sci. USA, 1989, vol. 86, pp. 7311-7315.
Pamela J. Keck et al. “Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF”, Science, 1989, vol. 246, pp. 1309-1312.
De Vries, C. et al. “Thefms-Like Tyrosine Kinase, a Receptor for Vascular Enothelial Growth Factor”, Science, 1992, vol. 255, pp. 989-991.
Terman, B. et al. “Identification of a new endothelial cell growth factor receptor tyrosin kinase”, Oncogene, 1991, vol. 6, 1677-1683.
Terman, B. et al. “Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor”, Biochem. and Biophys. Res. Comm., 1992, vol. 187, pp. 1579-1586.
Shibuya, M. et al. “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to thefmsfamily”, Oncogene, 1990, vol. 5, pp. 519-524.
Duan, D. et al. “A Functional Soluble Extracellular Region of the Platelet-derived Growth Factor (PDGF)B-Receptor Antagonizes PDGF-stimulated Responses”, The J. of Biol. Chem., 1991, vol. 266, pp. 413-418.
Hoshi, H. & McKeehan W. “Brain- and liver cell-derived factors are required for growth of human endothelial cells in serum-free culture”, Proc. Natl. Acad. Sci. USA, 1984, vol. 81, pp. 6413-6417.
Sanger, F. et al. “DNA sequencing with chain-terminating inhibitors”, Proc. Natl. Acad. Sci. USA, 1977, vol. 74, pp. 5463-5467.
Feinberg A. & Vogelstein B. “A Technique for Radiolabeling DNA Restriction Endonuclease Fragments to High Specific Activity”, Anal. Biochem., 1983, vol. 132, pp. 6-13.
Hunter W. & Greenwood F. “Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity”, Nature, 1962, vol. 194, pp. 495-496.
Scatchard, G. “The Attractions of Proteins for Small Molecules and Ions”, Annals NY Acad. of Sci., 1949, vol. 51, pp. 660-672.
Bikfalvi, A. et al. “Interaction of Vasculotropin/Vascular Endothelial Cell Growth Factor with Human Umbilical Vein Endothelial Cells: Binding, Internalization, Degradation, and Biological Effects”, J. of Cell. Phys., 1991, vol. 149, pp. 50-59.
Olsson, I. et al. “The receptors for Regulatory Molecules of Hematopoiesis”, Eur. J. Haematol, 1992, vol. 48, pp. 1-9.
Kim, K. et al. “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies”, Growth Factors, 1992, vol. 7, pp. 53-64.
Ueno, H. et al. “Inhibition of PDGF B Receptor Signal Transduction by Coexpression of a Truncated Receptor”, Science, 1991, vol. 252, pp. 844-848.
Maliszewski, C. et al. “Cytokine Receptors and B Cell Functions I. Recombinant Soluble Receptors Specifically Inhibit IL-1- and IL-4-Induced B Cell Activities in Vitro”, J. of Immunology, 1990, vol. 144, pp. 3028-3033.
Kendall, R. & Thomas, K. “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 10705-10709.
Millauer, B. et al. “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant”, Nature, 1994, vol. 367, pp. 576-579.
Millauer, B. et al. “High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis”, Cell, 1993, vol. 72, pp. 835-846.
Kendall Richard L.
Thomas, Jr. Kenneth A.
Basi Nirmal S.
Hand J. Mark
Merck & Co. , Inc.
Murphy Joseph
Tribble Jack L.
LandOfFree
Inhibitor of vascular endothelial cell growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitor of vascular endothelial cell growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor of vascular endothelial cell growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3548150